These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6727691)

  • 1. The effects of subcutaneous hormone implants during climacteric.
    Cardozo L; Gibb DM; Tuck SM; Thom MH; Studd JW; Cooper DJ
    Maturitas; 1984 Mar; 5(3):177-84. PubMed ID: 6727691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study.
    Brincat M; Magos A; Studd JW; Cardozo LD; O'Dowd T; Wardle PJ; Cooper D
    Lancet; 1984 Jan; 1(8367):16-8. PubMed ID: 6140343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmenopausal oestrogen replacement therapy with subcutaneous oestradiol implants.
    Suhonen S; Sipinen S; Lähteenmäki P; Laine H; Rainio J; Arko H
    Maturitas; 1993 Mar; 16(2):123-31. PubMed ID: 8483424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
    Furuhjelm M; Carlström K
    Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy.
    Grasso A; Baraghini F; Barbieri C; Dalla Vecchia E; Previdi AM; Di Renzo GC; Volpe A
    Maturitas; 1982 Apr; 4(1):19-26. PubMed ID: 6285153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term hormone implant therapy--hormonal and clinical effects.
    Barlow DH; Abdalla HI; Roberts AD; Al Azzawi F; Leggate I; Hart DM
    Obstet Gynecol; 1986 Mar; 67(3):321-5. PubMed ID: 3945443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy.
    Panay N; Versi E; Savvas M
    BJOG; 2000 Aug; 107(8):1012-6. PubMed ID: 10955434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen.
    Mattsson LA; Samsioe G
    Acta Obstet Gynecol Scand Suppl; 1985; 130():53-8. PubMed ID: 3859976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results.
    Burger HG; Hailes J; Menelaus M; Nelson J; Hudson B; Balazs N
    Maturitas; 1984 Dec; 6(4):351-8. PubMed ID: 6442755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subdermal estradiol pellets following hysterectomy and oophorectomy. Effect upon serum estrone, estradiol, luteinizing hormone, follicle-stimulating hormone, corticosteroid binding globulin-binding capacity, testosterone-estradiol binding globulin-binding capacity, lipids, and hot flushes.
    Lobo RA; March CM; Goebelsmann U; Krauss RM; Mishell DR
    Am J Obstet Gynecol; 1980 Nov; 138(6):714-9. PubMed ID: 6776814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial changes after long-term use of continuous oestrogen and cyclic progestogen.
    Fink BJ
    Maturitas; 1984 Apr; 5(4):277-80. PubMed ID: 6738374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a triphasic oestradiol/norethisterone acetate preparation with and without an oestriol component in the treatment of climacteric complaints.
    Hellberg D; Nilsson S
    Maturitas; 1984 Apr; 5(4):233-43. PubMed ID: 6429481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasia.
    Volpe A; Botticelli A; Abrate M; Dalla Vecchia E; Mantovani M; Carani C; Grasso A; Mazza V; Di Renzo GC
    Maturitas; 1982 Apr; 4(1):73-9. PubMed ID: 6285154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-related effects of a progestogen on the isoforms of serum gonadotrophins in 17 beta-oestradiol treated post-menopausal women.
    Wide L; Naessén T; Eriksson K; Rune C
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):651-8. PubMed ID: 8759177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures in practice. Hormone implantation.
    Thom MH; Studd JW
    Br Med J; 1980 Mar; 280(6217):848-50. PubMed ID: 6768415
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period.
    Hagen C; Christensen MS; Christiansen C; Stocklund KE; Transbøl I
    Acta Obstet Gynecol Scand; 1982; 61(3):237-41. PubMed ID: 6812385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of piperazine oestrone sulphate on serum oestrogen and gonadotrophin levels in post-menopausal women.
    Isaacs AJ; Havard CW
    Clin Endocrinol (Oxf); 1978 Oct; 9(4):297-302. PubMed ID: 719904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms.
    Høvik P; Sundsbak HP; Gaasemyr M; Sandvik L
    Maturitas; 1989 Mar; 11(1):75-82. PubMed ID: 2498620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.